Guangwei Du1, Mechelle M Lewis1,2, Christopher Sica3, Lan Kong4, Xuemei Huang1,2,3,5,6. 1. Department of Neurology, Penn State Hershey Medical Center, Hershey, PA. 2. Department of Pharmacology, Penn State Hershey Medical Center, Hershey, PA. 3. Department of Radiology, Penn State Hershey Medical Center, Hershey, PA. 4. Department of Public Health Sciences, Penn State Hershey Medical Center, Hershey, PA. 5. Department of Neurosurgery, Penn State Hershey Medical Center, Hershey, PA. 6. Department of Kinesiology, Penn State Hershey Medical Center, Hershey, PA.
Abstract
OBJECTIVE: Newer magnetic resonance imaging (MRI) techniques have shown promise in capturing early Parkinson disease (PD)-related changes in the substantia nigra pars compacta (SNc), the key pathological loci. Their translational value, however, is hindered by technical complexity and inconsistent results. METHODS: A novel yet simple MRI contrast, the T1w/T2w ratio, was used to study 76 PD patients and 70 controls. The T1w/T2w ratio maps were analyzed using both voxel-based and region-of-interest approaches in normalized space. The sensitivity and specificity of the SNc T1w/T2w ratio in discriminating between PD and controls also were assessed. In addition, its diagnostic performance was tested in a subgroup of PD patients with disease duration ≤2 years (PDE). A second independent cohort of 73 PD patients and 49 controls was used for validation. RESULTS: Compared to controls, PD patients showed a higher T1w/T2w ratio in both the right (cluster size = 164mm3 , p < 0.0001) and left (cluster size = 213mm3 , p < 0.0001) midbrain that was located ventrolateral to the red nucleus and corresponded to the SNc. The region-of-interest approach confirmed the group difference in the SNc T1w/T2w ratio between PD and controls (p < 0.0001). The SNc T1w/T2w ratio had high sensitivity (0.908) and specificity (0.80) to separate PD and controls (area under the curve [AUC] = 0.926), even for PDE patients (AUC = 0.901, sensitivity = 0.857, specificity = 0.857). These results were validated in the second cohort. INTERPRETATION: The T1w/T2w ratio can detect PD-related changes in the SNc and may be used as a novel, parsimonious in vivo biomarker for the disease, particularly for early stage patients, with high translational value for clinical practice and research. ANN NEUROL 2019;85:96-104.
OBJECTIVE: Newer magnetic resonance imaging (MRI) techniques have shown promise in capturing early Parkinson disease (PD)-related changes in the substantia nigra pars compacta (SNc), the key pathological loci. Their translational value, however, is hindered by technical complexity and inconsistent results. METHODS: A novel yet simple MRI contrast, the T1w/T2w ratio, was used to study 76 PDpatients and 70 controls. The T1w/T2w ratio maps were analyzed using both voxel-based and region-of-interest approaches in normalized space. The sensitivity and specificity of the SNc T1w/T2w ratio in discriminating between PD and controls also were assessed. In addition, its diagnostic performance was tested in a subgroup of PDpatients with disease duration ≤2 years (PDE). A second independent cohort of 73 PDpatients and 49 controls was used for validation. RESULTS: Compared to controls, PDpatients showed a higher T1w/T2w ratio in both the right (cluster size = 164mm3 , p < 0.0001) and left (cluster size = 213mm3 , p < 0.0001) midbrain that was located ventrolateral to the red nucleus and corresponded to the SNc. The region-of-interest approach confirmed the group difference in the SNc T1w/T2w ratio between PD and controls (p < 0.0001). The SNc T1w/T2w ratio had high sensitivity (0.908) and specificity (0.80) to separate PD and controls (area under the curve [AUC] = 0.926), even for PDEpatients (AUC = 0.901, sensitivity = 0.857, specificity = 0.857). These results were validated in the second cohort. INTERPRETATION: The T1w/T2w ratio can detect PD-related changes in the SNc and may be used as a novel, parsimonious in vivo biomarker for the disease, particularly for early stage patients, with high translational value for clinical practice and research. ANN NEUROL 2019;85:96-104.
Authors: Jeffrey H Kordower; C Warren Olanow; Hemraj B Dodiya; Yaping Chu; Thomas G Beach; Charles H Adler; Glenda M Halliday; Raymond T Bartus Journal: Brain Date: 2013-08 Impact factor: 13.501
Authors: Ruthger Righart; Viola Biberacher; Laura E Jonkman; Roel Klaver; Paul Schmidt; Dorothea Buck; Achim Berthele; Jan S Kirschke; Claus Zimmer; Bernhard Hemmer; Jeroen J G Geurts; Mark Mühlau Journal: Ann Neurol Date: 2017-09-16 Impact factor: 10.422
Authors: Dan Ma; Vikas Gulani; Nicole Seiberlich; Kecheng Liu; Jeffrey L Sunshine; Jeffrey L Duerk; Mark A Griswold Journal: Nature Date: 2013-03-14 Impact factor: 49.962
Authors: Susan R Criswell; Susan Searles Nielsen; Mark N Warden; Hubert P Flores; Jason Lenox-Krug; Sophia Racette; Lianne Sheppard; Harvey Checkoway; Brad A Racette Journal: J Occup Environ Med Date: 2019-08 Impact factor: 2.162
Authors: Wiesje Pelkmans; Ellen Dicks; Frederik Barkhof; Hugo Vrenken; Philip Scheltens; Wiesje M van der Flier; Betty M Tijms Journal: Hum Brain Mapp Date: 2019-06-03 Impact factor: 5.038
Authors: S Ponticorvo; R Manara; M C Russillo; R Erro; M Picillo; G Di Salle; F Di Salle; P Barone; F Esposito; M T Pellecchia Journal: Sci Rep Date: 2021-11-04 Impact factor: 4.379
Authors: Matthew F Glasser; Timothy S Coalson; Michael P Harms; Junqian Xu; Graham L Baum; Joonas A Autio; Edward J Auerbach; Douglas N Greve; Essa Yacoub; David C Van Essen; Nicholas A Bock; Takuya Hayashi Journal: Neuroimage Date: 2022-06-10 Impact factor: 7.400